Translational Oncology

www.transonc.com

Volume 9 Number 5 October 2016 pp. 453–457 453

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer[1]

Domenico Ribatti[*,†], Beatrice Nico[*], Simona Ruggieri[*], Roberto Tamma[*], Giovanni Simone[‡] and Anita Mangia[§]

[*]Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy; [†]IRCCS Istituto Tumori "Giovanni Paolo II," Bari, Italy; [‡]Pathology Department, IRCCS Istituto Tumori "Giovanni Paolo II," Bari, Italy; [§]Functional Biomorphology Laboratory, IRCCS Istituto Tumori "Giovanni Paolo II," Bari, Italy

Abstract

Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor is the most important angiogenic factor with proven significance in breast cancer, as it has been assessed in both experimental and clinical studies. Triple-negative breast cancer (TNBC) is a type of breast cancer which lacks estrogen, progesterone, and HER-2/neu receptors. MVD in both basal-like and TNBC is significantly higher than in non–basal-like and non-TNBC. In breast cancer and other malignancies, the development of agents that inhibit tumor angiogenesis has been an active area of investigation. In TNBC, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement. There is evidence that patients with TNBC may have a greater probability of obtaining some kind of clinical efficacy benefit from bevacizumab-based therapy.

Translational Oncology (2016) 9, 453–457

Angiogenesis in Breast Cancer

Breast carcinoma is a heterogeneous tumor made up of different cell clones, with different growth rates and metastatic potentials. The most important parameters which determine the prognosis of breast carcinoma are thought to be tumor size and grade, presence of lymph node metastasis, hormonal receptor status, and c-erb2 [1]. Breast tumors have been classified based on their gene expression profile and immunohistochemical expression of hormone receptors, HER2, cytokeratin 5/6, epidermal growth factor receptor (EGFR), p53, and BCL-2 [2].

Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion [3–5]. Breast cancer with high MVD have been found to have significant association with larger tumor size, high grade, lymph node metastasis, and poor prognosis [6–9]. Gasparini et al. [10] found a significant correlation between MVD and metastatic disease, recurrence-free survival, and overall survival (OS) in early breast cancer patients independent of their lymph node status. In a systematic review of the literature and meta-analysis, Uzzan et al. [11] found a statistically significant inverse relationship between angiogenesis, assessed by MVD, and survival, confirming that human invasive breast cancer is an angiogenesis-dependent malignancy.

Angiogenesis is important in the transformation of hyperplastic *in situ* epithelium to invasive carcinoma. In 1970, Gullino's group [12–15] observed that experimental breast cancer in rat and mouse gave rise to marked breast angiogenic activity that was lacking in adult

Address all correspondence to Prof. Domenico Ribatti, Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Policlinico-Piazza G. Cesare, 11, 70124, Bari, Italy.
E-mail: domenico.ribatti@uniba.it

[1] This work was supported by the grant "Traslocazione del gene Bcl6 nel carcinoma della mammella" from "Ricerca corrente 2016-IRCCS Istituto Tumori 'Giovanni Paolo II,' Bari, Italy" to D. R.
Received 19 May 2016; Revised 7 July 2016; Accepted 11 July 2016

1936-5233/16
http://dx.doi.org/10.1016/j.tranon.2016.07.002

gland. Moreover, just like the hyperplastic and dysplastic breast lesions more frequently subject to malignant change, premalignant lesions also induce a strong vasoproliferative response long before any morphological sign of malignant transformation can be observed. Normal murine mammary tissues only rarely induce neovascularization, whereas tissues from 30% of hyperplastic alveolar nodules and from 90% of murine mammary tumors are strongly angiogenic [14]. Multiple angiogenic factors are commonly expressed by invasive human breast cancers; at least six different proangiogenic factors, including acidic and basic fibroblast growth factor (bFGF), transforming growth factor beta-1 (TGFβ-1), platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin, have been identified, with the 121–amino acid isoform of vascular endothelial growth factor (VEGF) predominating [16].

Among the inflammatory cells involved in breast cancer, mast cells play a crucial role favoring angiogenesis and tumor progression. Mast cells are attracted in the tumor microenvironment by stem cell factor secreted by tumor cells and produce several angiogenic factors, including VEGF, bFGF, interleukin-8, and TGFβ-1, as well as matrix metalloproteinases, which promote tumor vascularization and invasiveness, respectively [17]. Kankkunen et al. [18] observed that significant increases in mast cell counts in breast carcinoma versus benign lesions are due to tryptase-containing mast cells. Moreover, tryptase-positive mast cells are significantly more numerous in the zone of invasion than elsewhere in malignant lesions. Breast cancer patients with metastases in the axillary nodes reveal greater numbers of mast cells in all nodes examined compared with patients without metastasis [19]. We have demonstrated that angiogenesis increases in parallel with the number of tryptase-positive mast cells and that their values are significantly higher in sentinel lymph nodes with micrometastases compared with those without [20].

VEGF in Breast Carcinoma

VEGF is the most important angiogenic factor with proven significance in breast cancer, as it has been assessed in both experimental and clinical studies. VEGF mRNA and/or protein expression has been detected at low level in normal human mammary gland [21]. VEGF induces tumor cell proliferation in mice models of breast cancer, and increased tumor proliferation is observed in transgenic mice with VEGF165 targeted to mammary epithelial cells under the control of mouse mammary tumor virus promoter 23 or in xenograft mice model generated by the injection of mammary tumor cells transfected with a VEGF165 or VEGF189 plasmid [22]. VEGF has been measured in sera and was detected at higher levels in sera of patients with stage III breast cancer as compared with stage I or II breast cancer and in healthy subjects [23,24]. Several studies have found an inverse correlation between VEGF expression and overall survival in both node-positive and node-negative cancer [10,25]. Moreover, increased VEGF expression has been associated with impaired response to tamoxifen or chemotherapy in patients with advanced breast cancer [26]. In fact, the two antiestrogens tamoxifen and toremifene, which are both used in the treatment of breast cancer, did not inhibit the estrogen-induced increase of VEGF mRNA expression.

An elevated number of VEGF receptor-3 (VEGFR-3)–positive cells were found in invasive breast cancer, and the expression of VEGFR-3 becomes upregulated in the endothelium of angiogenic blood vessels (Figure 1) [27]. The HER2 subtype is one of the most aggressive molecular variants of breast cancer, frequently associated with lymph node metastasis and poor prognosis. The aggressive behavior of these tumors may be explained in part by VEGF-C expression in tumor cells (Figure 1) [28].

In human breast cancer, the expression of VEGF correlates with mutant p53, and the combination of both mutated p53 and high VEGF levels has been associated with poor outcome [29]. The role of VEGF, hypoxia inducible factor-1 alpha (HIF-1α), and MVD in BRCA-1-2 carrier and BRCAX breast cancer has been retrospectively evaluated [30], and an increase of VEGF, HIF-1α expression, and MVD (Figure 2) in BRCA-1-2 carrier and BRCAX compared with the sporadic control group has been demonstrated. Other authors have demonstrated a relationship between BRCA-1 mutation and VEGF and HIF-1α expression in breast cancer patients [31,32] and their prognostic significance [33,34]. Bos et al. [35] investigated the correlation between the level of HIF-1α overexpression and VEGF, MVD, estrogen receptor, and p53 expression and demonstrated that the level of HIF-1α increases as the pathologic stage increases and is higher in poorly differentiated and more aggressive lesions than in the corresponding type of well-differentiated lesions. Increased levels of HIF-1α are associated with increased proliferation and increased expression of estrogen receptor and VEGF. Moreover, MVD and HIF-1α phenotype have a prognostic value in lymph node–positive and –negative breast cancer [36–38] and in invasive ductal carcinoma of the breast [9,11].

Angiogenesis in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a type of breast cancer which lacks estrogen, progesterone, and HER-2/neu receptors. Its features include young age, advanced stage at presentation, unfavorable histopathology, grade III, high proliferative index, lack of tubule formation, and high rate of metastases to distant organs, including lung and brain [39]. TNBC may be dissected into distinct subsets, including the basal-like and claudin-low subtypes, both of which have unique genetic characteristics and treatment responses. TNBC causes mortality when it metastasizes, and the average survival of advanced TNBC is 2 months, much shorter than the duration of survival observed in other subtypes of advanced breast cancer. Therapeutic treatment options for grade IV TNBC are very limited and often unsuccessful.

MVD in both basal-like and TNBC is significantly higher than in non–basal-like and non-TNBC [40]. Both basal-like and TNBC are no different in terms of the initial route of dissemination from non–basal-like and non-TNBC in that such dissemination occurs through lymph vessels [38]. Patients with operable TNBC show significantly higher levels of VEGF and shorter survival times [41]. Compared with non-TNBC, patients with TNBC had significantly higher intratumoral VEGF levels and significantly shorter recurrence-free survival and OS with a shorter time from diagnosis to relapse and from relapse to death [41]. Levels of VEGF correlated with poor outcome irrespective of tumor size, nodal status, histologic grade, age of patient, or type of relapse. Ray et al. [42] showed that VEGF induction in TN MDA-MB-231 breast cancer is regulated by serum amyloid A activating factor 1 transcription factor. Finally, it has been shown that TNBC correlates with higher lymphatic MVD and expression of VEGF-C and -D [43].

Antiangiogenesis in Breast Cancer

In advanced breast cancer, bevacizumab improved response rate but not progression-free survival (PFS) or OS when added to second-line capecitabine [44]. However, another phase III study demonstrated



Figure 1. Immunohistochemical expression of VEGF-C (A), and VEGFR-3 (B) in bioptic samples of human breast cancer (courtesy of Prof. Anca Maria Cimpean).

that the addition of bevacizumab to paclitaxel resulted in extension of PFS, but not OS, in metastatic breast cancer [45].

Three further phase III trials of bevacizumab in combination with chemotherapy in HER-2–negative metastatic breast cancer demonstrated an extension of PFS, but no effect on OS, when compared with chemotherapy alone [46–49]. The Ribbon 2 trial investigated the combination of bevacizumab with the physician's choice of capecitabine, a taxane (paclitaxel, nab-paclitaxel, or docetaxel), gemcitabine, or vinorelbine as second-line treatment for metastatic HER2 breast cancer [46]. As consequence of these disappointing results, the Food and Drug Administration withdrew its approval for bevacizumab in this indication. The efficacy of bevacizumab plus chemotherapy as neoadjuvant therapy for primary breast cancer compared with neoadjuvant chemotherapy alone has been reported [50].

In all studies of VEGFR tyrosine kinase inhibitors (TKIs), no OS benefit and no PFS effect have been seen, and adjuvant therapy was not beneficial. Sunitinib had shown single-agent activity in the treatment of metastatic breast cancer [51], and three phase III studies examining the addition of sunitinib to chemotherapy and one comparing single agent sunitinib to chemotherapy all failed to demonstrate improvement in PFS or OS [48,49,52–54].

In neoadjuvant trials, a 5% improvement in pathological complete response has been described when bevacizumab was combined with chemotherapy [55,56]. Axitinib has significant benefits only in patients who have previously received paclitaxel [57]. The pazopanib plus paclitaxel group has a significantly longer PFS than the paclitaxel-only group [58].

Antiangiogenesis in TNBC

Potential approaches in TNBC disease have included targeting VEGF, EGFR tyrosine kinases, and poly(ADP-ribose) polymerase 1. In the subgroup analysis, patients with TNBC had considerable improvement in overall response rate (ORR) and in the E2100 and the Avado trials [46,50], but no significant improvement was observed in the Ribbon 1 trial [49,50]. A meta-analysis was performed that included 621 patients with TNBC enrolled in these three trials. A significant improvement was observed in PFS and ORR with the combination therapy; however, no OS benefit was observed [59]. In the Ribbon 2 trial, in the subgroup analysis of 159 patients with TNBC, compared with chemotherapy alone, the addition of bevacizumab significantly improved ORR and PFS. There was a trend toward improved OS [60].

In the neoadjuvant setting, randomized studies of bevacizumab in combination with chemotherapy have yielded conflicting results. In the GeparQuinto trial, the rate of pathological complete response (pCR) was significantly higher with the addition of bevacizumab to the epirubicin plus cyclophosphamide followed by docetaxel regimen [61]. The benefit was restricted to the TNBC subpopulation, compared with a pathological complete response (pCR) rate of 7.7% and 7.8% with and without the addition of bevacizumab, respectively, among 1262 patients with HRþ tumors. However, these findings were not reproduced in the NSABP B-40



Figure 2. Immunohistochemical expression of VEGF (A), HIF-1α (B), and CD31 (C) in bioptic samples of human breast cancer.

trial [51]. In patients with metastatic TNBC, single-agent sunitinib led to a worse PFS than standard care in a phase II study [61].

Concluding Remarks

In breast cancer and other malignancies, the development of agents that inhibit tumor angiogenesis has been an active area of investigation. Strategies to inhibit tumor vessel growth include the use of bevacizumab, a monoclonal antibody targeting VEGF-A, and small-molecule TKIs. These targeted agents have been studied in combination both as monotherapies and in combination with cytotoxic chemotherapy. Combination of angiogenesis inhibitors with standard chemotherapy regimens in metastatic breast cancer so far has resulted in modest clinical efficacy, and TKIs have not shown efficacy in breast cancer treatment until today.

As TNBC cannot be treated with either hormonal therapy or anti-HER2 agents, standard chemotherapy is based on anthracycline and taxane combinations for the first line of treatment, followed by capecitabine at the time of progression [62]. In TNBC, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement. However, with chemotherapy alone, the residual disease risk in the breast and lymph nodes remains substantially higher, between 30% and 40% [63]. There is evidence that patients with TNBC may have a greater probability of obtaining some kind of clinical efficacy benefit from bevacizumab-based therapy [51,60].

Future antiangiogenesis trials should be more regimen, dose, and patient specific because these treatments act like targeted therapies in breast cancer and need to be more individualized. In this context, in order to provide a truly targeted therapy, it is vital to identify subsets of patients who display predictive markers for response and select these patients for treatment accordingly.

Acknowledgements

This work was supported by the grant "Traslocazione del gene Bcl6 nel carcinoma della mammella" from "Ricerca corrente 2016-IRCCS Istituto Tumori 'Giovanni Paolo II,' Bari, Italy" to D. R.

References

[1] Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, and Connolly JL, et al (2000). Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. *Arch Pathol Lab Med* **124**, 966–978.

[2] Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, and Jeffrey SS, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implication. *Proc Natl Acad Sci* **98**, 10869–10874.

[3] Arora R, Joshi K, Nijhawan R, Radotra BD, and Sharma SC (2002). Angiogenesis as an independent prognostic indicator in node-negative breast cancer. *Anal Quant Cytol Histol* **24**, 228–233.

[4] Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, and Gasparini G (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. *J Natl Cancer Inst* **84**, 1875–1887.

[5] Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. *N Engl J Med* **324**, 1–8.

[6] Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Palma PD, Meli S, Weidner N, and Gasparini G (1995). Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma—results of a multiparametric study. *Breast Cancer Res Treat* **36**, 205–217.

[7] Choi WWL, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C, and Young AN (2005). Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. *Mod Pathol* **18**, 143–152.

[8] Obermair A, Kurz C, Czerwenka K, Thoma M, Kaider A, Wagner T, Gitsch G, and Sevelda P (1995). Microvessel density and vessel invasion in lymph-node–negative breast cancer: Effect on recurrence-free survival. *Int J Cancer* **62**, 126–131.

[9] Tsutsui S, Kume M, and Era S (2003). Prognostic value of microvessel density in invasive ductal carcinoma of the breast. *Breast Cancer* **10**, 312–319.

[10] Gasparini G, Bonoldi E, Gatti C, Vinante O, Toi M, Tominaga T, Gion M, Dittadi R, Verderio P, and Boracchi P, et al (1997). Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. *J Natl Cancer Inst* **89**, 139–147.

[11] Uzzan B (2004). Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. *Cancer Res* **64**, 2941–2955.

[12] Brem S, Gullino P, and Medina D (1977). Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. *Science* **195**, 880–882.

[13] Brem SS, Jensen HM, and Gullino PM (1978). Angiogenesis as a marker of preneoplastic lesions of the human breast. *Cancer* **41**, 239–244.

[14] Gimbrone Jr MA and Gullino PM (1976). Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. *Cancer Res* **36**, 2611–2620.

[15] Maiorana A and Gullino PM (1978). Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. *Cancer Res* **38**, 4409–4414.

[16] Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, and Harris AL (1997). Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. *Cancer Res* **57**, 963–969.

[17] Ribatti D (2013). Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. *Immunol Lett* **152**, 83–88.

[18] Kankkunen JP, Harvima IT, and Naukkarinen A (1997). Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. *Int J Cancer* **72**, 385–388.

[19] Thoresen S, Tangen M, and Hartveit F (1982). Mast cells in the axillary nodes of breast cancer patients. *Diagn Histopathol* **5**, 65–67.

[20] Ribatti D, Finato N, Crivellato E, Guidolin D, Longo V, Mangieri D, Nico B, Vacca A, and Beltrami CA (2007). Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. *Histopathology* **51**, 837–842.

[21] Berse B, Brown LF, Van de Water L, Dvorak HF, and Senger DR (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. *Mol Biol Cell* **3**, 211–220.

[22] Hervé M-A, Buteau-Lozano H, Vassy R, Bieche I, Velasco G, Pla M, Perret G, Mourah S, and Perrot-Applanat M (2008). Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. *Am J Pathol* **172**, 167–178.

[23] Salven P, Perhoniemi V, Tykkä H, Mäenpää H, and Joensuu H (1999). Serum VEGF levels in women with a benign breast tumor or breast cancer. *Breast Cancer Res Treat* **53**, 161–166.

[24] Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, and Mori T, et al (1996). Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. *Clin Cancer Res* **2**, 821–826.

[25] Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, and Suzuki H, et al (1999). Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. *Cancer J Sci Am* **5**, 101–111.

[26] Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, and Klijn JG (2001). High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. *Cancer Res* **61**, 5407–5414.

[27] Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, and Alitalo K (1999). VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. *Am J Pathol* **154**, 1381–1390.

[28] Hoar FJ, Chaudhri S, Wadley MS, and Stonelake PS (2003). Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. *Eur J Cancer* **39**, 1698–1703.

[29] Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, and Bergh J (2001). The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. *Cancer Res* **61**, 2256–2260.

[30] Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, and Mangia A (2013). VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer. *PLoS One* **8**, e53070.

[31] Kawai H, Li H, Chun P, Avraham S, and Avraham HK (2002). Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. *Oncogene* **21**, 7730–7739.

[32] Dales JP, Garcia S, Bonnier P, Duffaud F, Carpentier S, Djemli A, Ramuz O, Andrac L, Lavaut M, and Allasia C, et al (2003). Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. *Ann Pathol* **23**, 297–305.

[33] Wang Z, Shi Q, Wang Z, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, and Zhang S, et al (2011). Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. *Pathol Res Pract* **207**, 505–513.

[34] Yan M, Rayoo M, Takano EA, Thorne H, and Fox SB (2009). BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. *Br J Cancer* **101**, 1168–1174.

[35] Bos R, Zhong H, Hanrahan CF, Mommers ECM, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, and van der Wall E (2001). Levels of hypoxia-inducible factor-1 during breast carcinogenesis. *J Natl Cancer Inst* **93**, 309–314.

[36] Costello P, McCann A, Carney DN, and Dervan PA (1995). Prognostic significance of microvessel density in lymph node negative breast carcinoma. *Hum Pathol* **26**, 1181–1184.

[37] Medri L, Nanni O, Volpi A, Scarpi E, Dubini A, Riccobon A, Becciolini A, Bianchi S, and Amadori D (2000). Tumor microvessel density and prognosis in node-negative breast cancer. *Int J Cancer* **89**, 74–80.

[38] Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, and Oberhuber G, et al (2002). Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node–positive breast cancer. *Clin Cancer Res* **8**, 1831–1837.

[39] Irvin WJ and Carey LA (2008). What is triple-negative breast cancer? *Eur J Cancer* **44**, 2799–2805.

[40] Mohammed RAA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, and Martin SG (2011). Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. *Mod Pathol* **24**, 774–785.

[41] Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, and Lewensohn R (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. *Ann Oncol* **20**, 1639–1646.

[42] Ray A, Dhar S, and Ray BK (2011). Control of VEGF expression in triple-negative breast carcinoma cells by suppression of SAF-1 transcription factor activity. *Mol Cancer Res* **9**, 1030–1041.

[43] Liu HT, Ma R, Yang QF, Du G, and Zhang CJ (2009). Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. *Int J Surg Pathol* **17**, 426–431.

[44] Miller KD (2005). Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J Clin Oncol* **23**, 792–799.

[45] Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* **357**, 2666–2676.

[46] Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, and Rugo HS (2011). RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer. *J Clin Oncol* **29**, 4286–4293.

[47] Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, and Puglisi F, et al (2010). Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer. *J Clin Oncol* **28**, 3239–3247.

[48] Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SYT, and Zhou X, et al (2011). RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. *J Clin Oncol* **29**, 1252–1260.

[49] Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, and Smith JW, et al (2011). Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III randomized, open-label trial. *Clin Breast Cancer* **11**, 82–92.

[50] Bear HD, Tang G, Rastogi P, Geyer Jr CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, and Fehrenbacher L, et al (2012). Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N Engl J Med* **366**, 310–320.

[51] Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, and DePrimo SE, et al (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* **26**, 1810–1816.

[52] Barrios CH, Liu M-C, Lee SC, Vanlemmens L, Ferrero J-M, Tabei T, Pivot X, Iwata H, Aogi K, and Lugo-Quintana R, et al (2010). Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. *Breast Cancer Res Treat* **121**, 121–131.

[53] Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, and Bischoff J, et al (2012). First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. *J Clin Oncol* **30**, 921–929.

[54] Crown JP, Dieras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, and Ramos M, et al (2013). Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. *J Clin Oncol* **31**, 2870–2878.

[55] Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier A-L, Abraham J, Thomas J, Provenzano E, and Hughes-Davies L, et al (2015). Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. *Lancet Oncol* **16**, 656–666.

[56] Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, and Hanusch C, et al (2013). Neoadjuvant bevacizumab and anthracycline-taxane–based chemotherapy in 678 triple-negative primary breast cancers; results from the GeparQuinto study (GBG 44). *Ann Oncol* **24**, 2978–2984.

[57] Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, and Rosbrook B, et al (2011). Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. *J Clin Oncol* **29**, 2459–2465.

[58] Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, and Arcangeli V, et al (2015). Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. *Lancet Oncol* **16**, 561–568.

[59] Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, and Yardley DA (2012). Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. *Breast Cancer Res Treat* **133**, 1067–1075.

[60] von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, and Kreienberg R, et al (2012). Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* **366**, 299–309.

[61] Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, and Kern KA, et al (2013). Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. *Breast* **22**, 650–656.

[62] Oakman C, Viale G, and Di Leo A (2010). Management of triple negative breast cancer. *Breast* **19**, 312–321.

[63] Carey LA (2011). Directed therapy of subtypes of triple-negative breast cancer. *Oncologist* **16**, 71–78.